Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Capricor Therapeutics (CAPR) EBITDA (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of EBITDA data on record, last reported at -$25.2 million in Q3 2025.

  • For Q3 2025, EBITDA fell 99.4% year-over-year to -$25.2 million; the TTM value through Sep 2025 reached -$81.2 million, down 137.92%, while the annual FY2024 figure was -$39.7 million, 79.07% down from the prior year.
  • EBITDA reached -$25.2 million in Q3 2025 per CAPR's latest filing, up from -$26.3 million in the prior quarter.
  • Across five years, EBITDA topped out at -$656973.0 in Q4 2023 and bottomed at -$26.3 million in Q2 2025.
  • Average EBITDA over 5 years is -$9.8 million, with a median of -$7.3 million recorded in 2023.
  • Peak YoY movement for EBITDA: skyrocketed 91.49% in 2023, then plummeted 841.57% in 2024.
  • A 5-year view of EBITDA shows it stood at -$6.2 million in 2021, then decreased by 24.58% to -$7.7 million in 2022, then surged by 91.49% to -$656973.0 in 2023, then tumbled by 841.57% to -$6.2 million in 2024, then plummeted by 306.67% to -$25.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$25.2 million in Q3 2025, -$26.3 million in Q2 2025, and -$23.6 million in Q1 2025.